


# Surfactant proteins analysis in perinatal deceased preterm twins among the Romanian population

Sinziana-Andra Ghitoi, MD<sup>a</sup>, Mariana Așchie, MD, PhD<sup>a,b,c</sup>, Georgeta Camelia Cozaru, MD, PhD<sup>a,b</sup>, Manuela Enciu, MD, PhD<sup>a,c</sup>, Elena Matei, PhD<sup>b,\*</sup> , Antonela-Anca Nicolau, MD, PhD<sup>a,b</sup>, Gabriela Izabela Bălțătescu, MD, PhD<sup>a,b</sup>, Nicolae Dobrin, PhD<sup>b,c</sup>, Roxana Elena Cîrjăliu, MD, PhD<sup>c</sup>, Ariadna Petronela Fildan, MD, PhD<sup>c</sup>

## Abstract

The molecular basis of the evaluation of children suspected of having disorders of surfactant proteins is still under discussion. In this study, we aimed to describe the morphological characteristics and to evaluate the immunohistochemical expression of surfactant proteins (surfactant protein A [SPA], surfactant protein B, and pro-surfactant protein C) in the preterm twins that deceased due to unexplained respiratory distress syndrome (n = 12). Results showed statistically significant positive correlations between surfactant protein B expressions and pulmonary hemorrhage ( $\rho = 0.678$ ;  $P < .05$ ), SPA levels, and Apgar score ( $\rho = 0.605$ ;  $P < .05$ ) and also expressions of SPA and bronchopneumonia ( $\rho = 0.695$ ;  $P < .05$ ). The fetuses and neonates of the same gestational age showed differences among surfactant proteins regarding the immunostaining expression. Our data evidence a marked interindividual variability in the expression of all 3 surfactant proteins among the cases analyzed (n = 12), suggesting the intervention of some individual and epigenetic factors during gestation that might influence surfactant protein production and consequently survival rate.

**Abbreviations:** ELBW = extremely low birth weight, GA = gestational age, PI = ponderal index, RDS = respiratory distress syndrome, SPA = surfactant protein A, SPB = surfactant protein B, SPC = surfactant protein C, SPD = surfactant protein D.

**Keywords:** hemorrhage, preterm twins, respiratory distress syndrome, stillborn, surfactant proteins

## 1. Introduction

According to the literature, multiple pregnancies are associated with an increased risk of mortality compared to single fetal pregnancies.<sup>[1,2]</sup> In this sense, multifetal pregnancies represent 3% of pregnancies, of which 98% are twins, more frequently exposed to the phenomenon of premature birth, and 10% of them are stillbirths.<sup>[3]</sup> Identifying the causes of neonatal morbidity and mortality is essential for planning its reduction since respiratory diseases are the biggest contributor to morbidity and mortality in premature and low-birth-weight infants.<sup>[4]</sup>

At the same time, studies on twins have shown the common involvement of genetic and environmental risk factors in the etiopathogenesis of these diseases.<sup>[5]</sup> The physiologic transition from fetal to neonatal period requires the production of pulmonary surfactant, a complex mixture of 10% proteins, 70% to

80% phospholipids, and 10% neutral lipids, which are mostly produced by the type II alveolar cells.<sup>[6]</sup> The main role of surfactants is to reduce the surface tension within the alveoli to avoid alveolar collapse, contribute significantly to pulmonary immunity processes, being involved in viral neutralization, clearance of bacteria, fungi, apoptotic cells, and regulation of inflammation. The inability of premature neonates to produce surfactants and the immaturity of their lungs represent the primary etiologies of respiratory distress syndrome (RDS). In the alveoli, the surfactant is arranged in the form of myelin tubes. There are 4 specific surfactant proteins, 2 hydrophilic proteins with high molecular weight (surfactant protein A [SPA] and surfactant protein D [SPD]) and 2 lipophilic proteins with low molecular weight (surfactant protein B [SPB] and surfactant protein C [SPC]), which are highly interconnected in their functions.<sup>[6]</sup>

All authors contributed equally to this work.

This work was supported by the S-GEMINI project, in the framework of the Ovidius University of Constanta biomedical grant competition; contract number October 17, 2019. Research activities of this grant were approved by the decision with the number November 22, 2019, by the Ethics Commission for approving clinical trials and research papers.

This research was performed in the Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology from the Ovidius University of Constanta, POSCCE 2.2.1. Project ID: 1844, SMIS code: 48750, CEDMOG, contract 627/11.03.2014.

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article.

<sup>a</sup> Clinical Service of Pathology, "Sf. Apostol Andrei" Emergency County Hospital, Constanta, Romania, <sup>b</sup> Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology, "Ovidius" University of Constanta, CEDMOG, Constanta, Romania, <sup>c</sup> Medicine Faculty, "Ovidius" University of Constanta, Constanta, Romania.

\*Correspondence: Elena Matei, Center for Research and Development of the Morphological and Genetic Studies of Malignant Pathology, "Ovidius" University of Constanta, CEDMOG, 145 Tomis Blvd., Constanta 900591, Romania (e-mail: sogorescuelena@yahoo.com).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Ghitoi SA, Așchie M, Cozaru GC, Enciu M, Matei E, Nicolau AA, Bălțătescu GI, Dobrin N, Cîrjăliu RE, Fildan AP. Surfactant protein analysis in perinatal deceased preterm twins among the Romanian population. *Medicine* 2022;101:30(e29701).

Received: 15 November 2021 / Received in final form: 23 April 2022 / Accepted: 13 May 2022

<http://dx.doi.org/10.1097/MD.00000000000029701>

With the recent increase in the use of assisted reproductive techniques, the frequency of twin pregnancies is progressively increasing, while there is little information known about how the disorders of surfactant affect preterm infants and twins, it becomes important to gain more knowledge on this topic.

In our study, the morphological characteristics in correlation with the expressions of SPA, SPB, and pro-SPC were assessed, being the first study on the protein variants of the surfactant on the preterm twins among the Romanian population.

## 2. Materials and Methods

### 2.1. Case selection

Our study used premature (<37 weeks of gestation) infants born in Constanta, Romania, from multiple gestations during the last 5 years (2021–2017), being chosen from the patients' bases of the Neonatology Department and the Clinical Service of Pathology, "Sf. Apostol Andrei" Emergency County Hospital.

Among the total number of newborn cases from twin pregnancies ( $n = 12$ ), 6 were stillborn and the other 6 were liveborn. All cases were chosen without other excluding criteria, besides genetic syndromes, and other associated pathologies.

The study was approved by the Ethics Committees of the "Sf. Apostol Andrei" Emergency County Hospital, from Constanta. Gestational age (GA), gender, mode of delivery, birth order, and maternal and neonatal clinical history were obtained from their medical records. All newborns did not receive the exogenous surfactants at their birth.

### 2.2. Morphological and clinical characteristics of cases

An autopsy was performed for each case, to determine the cause of death. The stillborn underwent external examination, with the performance of characteristic measurements (birth weight, length, cranial, thoracic, and abdominal perimeter) and internal examination, by analyzing the cranial cavity, thymus, lungs, heart, and large vessels, organs of the abdominal cavity, kidneys, and adrenal glands. The cases were named in capital letters, in alphabetical order, marking with the numbers 1 and 2 the pairs of fetuses and with a single number the child who died from that pair.

Preterm birth is defined as birth before 37 complete weeks of gestation. Preterm birth is classified according to the GA as late preterm (between 32 and 37 weeks of gestation), very preterm (from 28 to 32 weeks of gestation), and extremely preterm (<28 weeks of gestation).<sup>[7]</sup> Also, the term stillborn refers to the death in utero of a fetus with a GA  $\geq 20$  weeks of pregnancy.

Birth weight among children born preterm can be classified as extremely low birth weight (ELBW; <1000 g), very low birth weight (<1500 g), low birth weight (1500–2500 g), and normal birth weight (>2500 g).<sup>[8,9]</sup> Infants born small for gestational age were identified based on World Health Organization-specific references on fetal birth weight being less than the 10th percentile for GA. The weight-length ratio was calculated using the Rohrer ponderal index (PI), by the formula  $100 \times \text{weight in grams/length in centimeters}$ , which has normal values in newborns between 2.2 and 3, irrespective of weeks of gestation, child's sex, and maternal parity.<sup>[10,11]</sup>

The gravidity of a woman is defined as the number of pregnancies that the woman had, regardless of the stage of the pregnancies, so primigravida refers to a woman in her first pregnancy, while multigravida is a woman who has been pregnant more than once. The parity refers to the number of pregnancies that a woman had with GAs of over 24 weeks, which led to childbirth, even though the child was stillborn or was born alive, so a primiparous woman is a woman who has given birth once, while a multiparous woman has given birth more than once.<sup>[18]</sup>

The Apgar score is a method used to assess the status of a newborn immediately after birth. The Apgar score is composed

of 5 elements: heart rate, respiratory effort, muscle tone, reflex irritability, and skin color. It has values between 0 and 10, the normal values being between 7 and 10; the score is reported at 1 and 5 minutes after birth and then every 5 minutes, for the first 20 minutes for infants with a score of <7 at birth.<sup>[8]</sup> A stillborn is defined as a baby born beginning with 28 weeks of gestation or with a birth weight of at least 1000 g, without any sign of life.<sup>[12]</sup>

### 2.3. SPA, SPB, and pro-SPC determinations by immunohistochemical techniques

Fragments of organs with representative lesions taken from the autopsy were fixed, paraffin embedded, and subsequently stained with hematoxylin-eosin. The sampled lung tissue fragments were subjected to immunohistochemical examination, using polyclonal antibodies such as the SPA antibody, SPB antibody, and pro-SPC antibody.

Immunohistochemical examination was performed in compliance with the indications recommended by the manufacturer (Novus Biologicals). For immunohistochemical tests, we used formalin-fixed, paraffin-embedded tissue, being sectioned at 4  $\mu\text{m}$  thickness. The staining protocol, as recommended by the producer, included deparaffined using xylene and decreasing grades of alcohol, heat-induced epitope retrieval in pH = 6 citrate buffer using a pressure cooker, incubating the antibodies overnight at 4 °C with corresponding dilutions (SPA, 1:300; SPB, 1:300; pro-SPC, 1:100). For detection, we used a polymer detection kit (peroxidase, 2.5% normal horse serum-HRP and DAB reagent; Vector Laboratories) and finally counterstained with hematoxylin and mounting.

Immunoreaction of SPA is considered positive in alveolar type II cells, non-ciliated bronchial cells, and a subset of alveolar macrophages. SPB positivity and pro-SPC reactivity are considered in alveoli. The expressions for each marker, SPA, SPB, and pro-SPC, were evaluated as absent (–), weakly positive (+), and intense positive (++) compared to the histopathological normal area without inflammation or a proliferative lesion in the same specimens. For the evaluation of the expression of the proteins, the histopathological normal area of the lungs was used as a control, especially type II alveolar cells (positive for SPA, SPB, and pro-SPC) and the bronchiolar epithelial cells (weak positive for SPA and pro-SPC and intense positive for SPB).

### 2.4. Statistical analysis

Obtained results were presented as mean values with standard errors for maternal age, GA, weight at birth, length of the fetuses, and being using the SPSS Statistics software package (version 17.01; IBM). Because of the interindividual variability of the parameters, the Shapiro-Wilk test was applied for testing the normality distribution.

To analyze the correlations between morphological characteristics and expression of surfactant proteins by immunohistochemical tests (SPA, SPB, and pro-SPC), were used the Spearman's ranks correlation coefficient, and  $P < .05$  was considered statistically significant.

## 3. Results

During the study period, from all cases of necropsies on children ( $n = 315$ ), were analyzed the autopsy records of premature newborns from twin pregnancies ( $n = 12$ ). The data from the quantification of the parameters are presented in Table 1.

The mean age of the mothers was  $27.25 \pm 1.69$  years (range, 21–38 years). The mean GA was  $28.17 \pm 1.06$  weeks (range, 23–36 weeks), being shorter in boy-boy pairs than in boy-girl and girl-girl pairs.

In the studied group, stillborn ( $n = 6$ ) and liveborn ( $n = 6$ ) cases were identified. The liveborn presented a 5-minute Apgar score between 1 and 6. The weight at birth varied from 600 to

2900 (mean,  $1132.5 \pm 189.03$ ) g. The mean length of the fetuses was  $33.75 \pm 1.22$  cm. The fetus length at birth was smaller in the population of preterm twins born from multiparous multigravida mothers compared to the ones born from nulliparous primigravida. A single fetus associated a congenital malformation, represented by giant encephalocele, with anal imperforation and facial dimorphism. Four of 6 stillborn fetuses came from multiparous mothers, with an age under 30 years.

Histopathological examination of the lung tissue showed inflammatory, hemorrhagic, and pulmonary atelectasis changes.

Meningeal and renal hemorrhage, circumscribed purulent collections (in liveborn), and congenital malformations were observed (Table 2). All cases showed pulmonary lesions, and 8 cases were associated with extrapulmonary lesions. The most common lesions were pulmonary hemorrhage in 58.33% of cases and meningeal and renal hemorrhage in 50% of cases.

Table 3 presents the expression of surfactant proteins by immunostaining technique at the pulmonary level on samples recovered from the studied group. Immunohistochemical examination (Fig. 1) shows a negative response to SPA in 6

**Table 1****The morphological characteristics of the cases from the studied group.**

Cases	Sex	Weight at birth (g)	Fetus length (cm)	PI (g/cm <sup>3</sup> )	GA (wk)	5-min Appgar score	Maternal age (y)	G and P	Prematurity grade
A1	M	640	30	2.37	23	1	27	G3P2	ELBW
A2	M	600	29	2.46	23	Stillborn	27	G3P2	ELBW
B1	M	1150	34	2.9	30	6	25	G1P1	VLBW
B2 <sup>a</sup>	F	900	36	1.93	30	Stillborn	25	G1P1	ELBW
C1	F	1300	30	4.8	27	Stillborn	23	G5P3	VLBW
C2	F	1050	33	2.9	27	Stillborn	23	G5P3	VLBW
D1*	F	700	33	1.95	26	Stillborn	38	G4P2	ELBW
D2*	F	650	32	2	26	2	38	G4P2	ELBW
E1	F	2900	45	3.2	36	1	32	G1P1	NBW
F1	M	1800	32	5.5	32	Stillborn	27	G1P1	LBW
G1	F	1100	36	2.36	29	5	21	G1P1	ELBW
G2	F	800	35	1.87	29	5	21	G1P1	ELBW

B2<sup>a</sup>: cross-sectional presentation.

ELBW = extremely low birth weight, F = female, G = gravidity, GA = gestational age, LBW = low birth weight, M = male, NBW = normal birth weight, P = parity, PI = ponderal index, VLBW = very low birth weight.

\*D1, D2: mothers diagnosed with HIV; ELBW, <1000g; VLBW, <1500g; LBW, 1500 to 2500g; NBW, >2500g.

**Table 2****Spectrum of pulmonary and extrapulmonary lesions on necropsy macroscopic examination of the studied group.**


Cases	Lung injuries	Extrapulmonary lesions
A1 liveborn	Bilateral pulmonary atelectasis, pulmonary hemorrhage	Meningeal hemorrhage, renal hemorrhage
A2 stillborn	Bilateral pulmonary atelectasis	Meningeal hemorrhage and edema, renal and adrenal hemorrhage
B1 liveborn	Bilateral bronchopneumonia, left pleurotomy under the drain	Purulent peritonitis
B2 stillborn	Acute bilateral bronchopneumonia	Acute enterocolitis
C1 stillborn	Bilateral pneumonia, total bilateral atelectasis	-
C2 stillborn	Pulmonary hemorrhage	-
D1 stillborn	Atelectasis, bilateral pulmonary hemorrhage	Edema and meningeal hemorrhage, adrenal hemorrhage
D2 liveborn	Bilateral pneumonia	Plurivisceral hemorrhage, pericardial effusion, congenital malformation: giant encephalocele, anal imperforation, rectovaginal fistula, facial dimorphism
E1 liveborn	Pulmonary hemorrhage	-
F1 stillborn	Pulmonary hemorrhage	-
G1 liveborn	Pneumopathy and pulmonary hemorrhage	Plurivisceral hemorrhage, cerebral edema
G2 liveborn	Pulmonary hemorrhage	Plurivisceral hemorrhage, left occipital hematoma, hemorrhagic gastritis

**Table 3****Expression of surfactant proteins by immunostaining technique at the pulmonary level on samples recovered from the studied group.**

Cases	Weight at birth (g)	GA (wk)	SPA	SPB	Pro-SPC
A1 liveborn	640	23	Negative (-)	Weak positive (+)	Negative (-)
A2 stillborn	600	23	Negative (-)	Weak positive (+)	Negative (-)
B1 liveborn	1150	30	Weak positive (+)	Negative (-)	Negative (-)
B2 stillborn	900	30	Weak positive (+)	Negative (-)	Negative (-)
C1 stillborn	1300	27	Weak positive (+)	Negative (-)	Negative (-)
C2 stillborn	1050	27	Negative (-)	Weak positive (+)	Negative (-)
D1 stillborn	700	26	Negative (-)	Weak positive (+)	Weak positive (+)
D2 liveborn	650	26	Weak positive (+)	Negative (-)	Weak positive (+)
E1 liveborn	2900	36	Negative (-)	Intense positive* (++)	Weak positive (+)
F1 stillborn	1800	32	Negative (-)	Weak positive (+)	Negative (-)
G1 liveborn	1100	29	Intense positive (++)	Intense positive (++)	Weak positive (+)
G2 liveborn	800	29	Intense positive (++)	Intense positive (++)	Weak positive (+)

GA = gestational age, SPA = surfactant protein A, SPB = surfactant protein B, SPC = surfactant protein C.

\*Samples are intense positive (++) in the areas of alveolitis and pulmonary atelectasis.



**Figure 1.** The immunohistochemical antibody expression of the cases from the studied group: (A) SPA intense positive in alveolar spaces; controls positive ( $\times 40$ ); (B) SPB intense positive in the areas of pulmonary atelectasis; controls positive ( $\times 200$ ); (C) pro-SPC weak positive in type II alveolar epithelial cells; controls positive ( $\times 100$ ); (D) SPA weak positive ( $\times 100$ ); (E) SPB weak positive ( $\times 100$ ); (F) pro-SPC negative ( $\times 200$ ). SPA = surfactant protein A, SPB = surfactant protein B, SPC = surfactant protein C.

cases (50%), a weak positive response in 4 cases (33.33%), and an intense positive response in 2 cases (16.67%). Regarding immunoreactivity to SPB, 4 cases (33.33%) had a negative response, while 3 cases (25%) were intense positive in the areas of leukocyte alveolitis and pulmonary atelectasis, while the others were weakly positive (41.67%). Evaluation of pulmonary tissue cases with pro-SPC showed negativity in 7 cases (58.33%), weak positivity in 5 cases (41.67%), and no case of intense focal positivity.

The correlations between SPA, SPB, and pro-SPC expressions at the pulmonary level, GA, and birth weight are shown in Table 4. The expression of surfactant proteins was not correlated with GA and birth weight of cases from the studied group.

Immunohistochemical expression of surfactant proteins in correlation with the type of pulmonary lesions and 5-minute Apgar score are shown in Table 5. SPA was positively correlated with bronchopneumonia ( $\rho = 0.695$ ;  $P < .05$ ) and 5-minute Apgar score ( $\rho = 0.605$ ;  $P < .05$ ). Immunohistochemical expression of SPB was positively correlated with pulmonary hemorrhage ( $\rho = 0.678$ ;  $P < .05$ ).

In Table 6, statistical analyses evidenced a significant positive correlation ( $\rho = 0.850$ ;  $P < 0.01$ ) between the expression of the birth weight and GA. Also, a significant positive correlation ( $\rho = 0.723$ ;  $P < 0.01$ ) is between the GA and fetus length.

#### 4. Discussion

The present study examined the protein variants of the pulmonary surfactant in a population consisting of 12 preterm twins, perinatally deceased due to acute RDS. The sampled lung tissue

**Table 4**

**Surfactant protein expressions at the pulmonary level in correlation with GA and birth weight, on cases from the studied group.**

Spearman rank correlation coefficient		SPA	SPB	Pro-SPC
Birth weight (g)	$\rho$	0.076	-0.074	-0.024
	Sig. (2 tailed)	0.814	0.818	0.940
GA (wk)	$\rho$	0.200	-0.023	0.074
	Sig. (2 tailed)	0.533	0.945	0.819

$\rho$  = Spearman rank correlation coefficient, GA = gestational age, SPA = surfactant protein A, SPB = surfactant protein B, SPC = surfactant protein C, Sig. (2 tailed) =  $P$  values.

fragments from the autopsies were subjected to immunohistochemical examination, using the polyclonal antibodies SPA, SPB, and pro-SPC.

The major glycoprotein is SPA, which is released into the alveolar lumen from cytoplasmic lamellar bodies from the type II alveolar epithelial cells, although SPA can be found in small quantities also in the pseudostratified epithelium of the airways, in the non-ciliated bronchiolar cells, and the submucosal glands of the trachea.<sup>[13]</sup> SPA has a role in the tubular myelin formation, the formation of the surface's film, and contributes to the inflammatory response by binding with the microbial pathogens that invade the lungs.<sup>[14,15]</sup> SPA is also found in small quantities in extrapulmonary sites such as small and large intestines, mesentery, epithelium, salivary glands, prostate, thymus, amniotic

**Table 5**  
Correlations between immunohistochemical expression of surfactant proteins and the clinicomorphological characteristics on cases from the studied group

Spearman rank correlation coefficient		SPA	SPB	Pro-SPC
Atelectasis	$\rho$	-0.391	-0.027	-0.239
	Sig. (2 tailed)	0.208	0.933	0.454
Pulmonary hemorrhage	$\rho$	-0.267	0.678*	0.371
	Sig. (2 tailed)	0.401	0.015	0.235
Bronchopneumonia	$\rho$	0.695*	-0.496	-0.029
	Sig. (2 tailed)	0.012	0.101	0.930
5-min Apgar score	$\rho$	0.605*	0.287	0.446
	Sig. (2 tailed)	0.037	0.365	0.146

$\rho$  = Spearman rank correlation coefficient, SPA = surfactant protein A, SPB = surfactant protein B, SPC = surfactant protein C, Sig. (2 tailed) = *P* values.

\*Correlation is significant at the 0.05 level (2 tailed).

**Table 6**  
Correlations between GA, birth weight, and fetus length on cases from the studied group.

Spearman rank correlation coefficient		Birth weight (g)	Fetus length (cm)
GA (wk)	$\rho$	0.850*	0.723*
	Sig. (2 tailed)	0.000	0.008

$\rho$  = Spearman rank correlation coefficient, GA = gestational age, Sig. (2 tailed) = *P* values.

\*Correlation is significant at the 0.01 level (2 tailed).

fluid, and lacrimal apparatus.<sup>[16]</sup> SPA formation is stimulated by interleukin-1, adenosine monophosphate, and a low concentration of corticosteroids, while a high concentration of corticosteroids inhibits the SPA secretion.<sup>[17]</sup>

SPB is produced in Clara cells as pro-SPB and the type II alveolar cells as mature SPB. The processing of pro-SPB by the Clara cells into active mature SPB consists of a complex process of proteolytic cleavage.<sup>[18]</sup> SPB has an essential role in the absorption and surface distribution of phospholipids, in the fusion of multivesicular bodies into lamellar structures, and it helps the organization of phospholipids into myelin tubes and is involved in their transport at the air-liquid interface. In case of SPB deficiency, the structure of the lamellar body will be disorganized. SPB is also involved in the posttranslational modification of SPC. Because mature SPC is formed from pro-SPC after cleavage in the lamellar bodies, in case of SPB deficiency, this process will be disrupted, which will lead to the accumulation of pro-SPC and a deficiency of mature SPC. There is a hypothesis that suggests that SPB deficiency also affects the recycling of SPA, which will lead to increased SPA in the airspaces and decreased levels in the type II alveolar cells. Exogenous surfactant provides just a transitory improvement in gas exchange in case of SPB deficit and does not normalize the surfactant composition and function, so the patients require lung transplantation usually in the first year of life.<sup>[19]</sup>

SPC is produced exclusively in the lungs by the type II alveolar cells. SPC has a role in film formation and stabilization, decreasing the risk of alveolar collapse. SPC does not interact with SPA and is not essential for the formation of myelin tubes. SPC deficiency has multiple manifestations, from RDS developed in the first hour after birth to interstitial lung disease developed in childhood and adulthood. One study performed on mice with negative expression of SPC showed that they developed enlargement of the airspaces and chronic pneumonitis until the age of 6 months, so SPC is not essential for the perinatal transition to breathing, as individuals lacking SPC survive but develop a variety of interstitial or fibrotic lung

disease outcomes. Corticosteroids are the main treatment for SPC deficiency, sometimes in association with azithromycin and hydroxychloroquine.<sup>[20]</sup> SPD is a molecule with pulmonary and extrapulmonary localization on the apical luminal surface of the respiratory epithelium, included in the collectin family, like SPA, whose distribution and properties partially overlap with SPD, which is why the expression of this protein was not determined in this article. The most important function of SPD in the lungs is to regulate pulmonary surfactant lipid levels and is also considered a potential role in involvement in phospholipid homeostasis at extrapulmonary sites, although this has not been fully demonstrated.<sup>[21-23]</sup>

Studies of explants from the human lung have shown that SPA is expressed in the epithelial cells of the main and segmental bronchi from the 21st week of gestation, while in the alveolar cells, SPA is expressed from the 29th week of gestation. SPB and SPC are expressed in the epithelial cells of the terminal airways from the 15th week of gestation and in the alveolar cell from the 25th week of gestation.<sup>[24]</sup> Thus, it is important to determine whether these surfactant disorders also include protein deficiencies, especially for the differentiated postpartum therapeutic approach. It is also imperative to find out, in the case of twin pregnancies, if only one or both children experience a qualitative protein disorder to establish the causal sequence, which may open the door in the future to other studies in the field, useful in increasing survival.

All subjects included in this study were born preterm, with a preponderance of extremely preterm newborns (A1/A2, C1/C2, and D1/D2), followed by 2 pairs of very preterm infants (B1/B2 and G1/G2), while 2 cases were late preterm (E1 and F1). RDS represents the first cause of morbidity and mortality in the first year of life of preterm neonates, due to insufficient secretion, inadequate production, or inactivation of the surfactant caused by lung immaturity.<sup>[25]</sup> Data from literature, supported also by the results of the present study, showed that the incidence of RDS is inversely proportional to the GA.<sup>[26,27]</sup>

The immunohistochemical examination showed a negative or a weak positive response to SPA, SPB, and pro-SPC in the majority of cases of the studied group (10 of 12; 83.33%). One premature pair of neonates (G1/G2) with ELBW, born at 29 weeks of gestation from a young primiparous primigravida (of 21 years old), presented intense positive reactions for both SPA and SPB and weak reactivity for pro-SPC. The only case (E1) with intense positive expression for SPB, exclusively in the areas of alveolitis, was born at 36 weeks of gestation, with normal birth weight, from a 32-year-old mother, at the first pregnancy. The reactivity of the surfactant proteins was not correlated with GA and birth weight, suggesting an interindividual variability. As the study by Cau et al<sup>[8]</sup> showed, other factors may affect surfactant production and influence the survival rate of preterm infants.

In this study, 11 of 12 (91.66%) preterm twins were born with low birth weight, of which 7 had ELBW (<1000g). Birth weight was not correlated with a specific deficit of surfactant proteins but was in direct relationship with mortality. These results are in concordance with previous studies that had shown that in infants with birth weight <2500g, the risk of death has been around 200× higher compared to normal-birth-weight infants.<sup>[8,28,29]</sup>

Regarding the length at birth, 10 of 12 (83.33%) preterm twins presented lower fetus length at birth, according to their gestation age, and low PI. Similar results were reported by authors, which showed that infants with small fetus length at birth and low PI have a high risk of morbidity and mortality.<sup>[30]</sup>

From the population of preterm twins that we analyzed, 8 of 12 (75%) were female. Other studies performed on singleton term neonates have shown that the masculine sex has a higher risk for developing RDS.<sup>[31,32]</sup> It was believed that female lungs produce surfactants earlier during gestation because of the different hormonal profiles. It is known that estrogens have a

positive effect on surfactant synthesis and the secretion of SPA and SPB, by increasing the number of alveolar type II cells.<sup>[32]</sup> A possible explanation of the female predominance observed in our study may be the fact that all the newborns were from twin pregnancies.

In this study, all the infants who were born alive had a 5-minute Apgar score <7, and a significant positive association between negative expression of SPA and a 5-minute Apgar score was found. These results were also previously observed in the study by Chambliss et al,<sup>[33]</sup> who showed that a 5-minute Apgar score of ≤7 is a risk factor for developing RDS.

Half of the babies included in this study were stillborn, of whom 4 were extremely preterm and 2 were very preterm. The maternal age was <28 years in 5 cases, one mother of 38 years of age who also had an HIV infection associated, while 4 mothers were multiparous and multigravida. Four stillborns presented negative SPA, 2 negative SPB, and 5 negative pro-SPC. The main risk factors for stillbirth were previously identified in a systematic review of 96 studies, which found the advanced maternal age, primiparity, small fetus length at birth, maternal smoking, maternal obesity, diabetes, and hypertension as the most frequent risk factors associated with this condition, but further studies will be necessary to identify whether there is an association between a certain protein deficit and stillbirth.<sup>[34]</sup>

In our study, the infants born from multigravida and multiparous mothers (6 of 12) were extremely preterm, 4 of them were stillborn, while the other 2 had low 5-minute Apgar score (of 1, respectively 2). We noticed that 4 of these 6 fetuses presented negative SPA and 4 negative SPB. Multiple gestations have been previously suggested to be associated with RDS in preterm infants, especially in the case of advanced maternal age.<sup>[31]</sup> In another study performed on singleton infants,<sup>[35]</sup> parity was associated with respiratory complications and increased risk of developing RDS. The underlying mechanism and the possible association between the surfactant protein deficiency and the parity of the mothers are still unclear, and further studies need to be performed in this area.

In the present study, a statistically significant positive correlation between SPA expression and pulmonary hemorrhage was noticed. From the 7 cases with pulmonary hemorrhage from our study, 5 of them presented negative expression of SPA. Multiple other studies showed that SPA deficiency increases apoptosis and decreases cell viability, induces an inflammatory reaction, and causes acute lung injury.<sup>[36,37]</sup> Pulmonary hemorrhage may be associated with RDS, possibly due to high capillary pressure caused by hypoxia, heart failure, and volume overload. Following the endothelial damage, neutrophils will be released, which will lead to increased values of proteases, cytokines, and oxygen-free radicals. These components will damage the type II alveolar cells that produce SPs, resulting in lower levels of SPs.<sup>[38]</sup>

SPA plays a major role in protecting the lungs against infections, by enhancing the attachment of phagocytic cells with pathogens and the clearances.<sup>[39]</sup> The 4 twins with bronchopneumonia from this study showed nonintense positive SPA and negative SPB, similar to other studies from literature that showed that bacterial infection is associated with low levels of SPA and SPB.<sup>[39]</sup>

In our study, 4 newborns also presented pulmonary atelectasis, without any specific correlation with a certain surfactant protein. Because surfactant prevents lung collapse at low volumes by reducing the surface tension, surfactant deficiency can lead to atelectasis, which is clinically evident in the case of neonatal RDS, congenital SPB deficiency, and pulmonary alveolar proteinosis. In the presence of protein surfactant deficiencies, children are more likely to develop atelectasis compared with adults, due to the lack of Kohn pores and Lamber canals, which allow collateral ventilation of the obstructed alveoli.<sup>[40]</sup>

The infants from our study presented numerous extrapulmonary lesions. Half of them presented at least one extrapulmonary hemorrhage: 5 (41.66%) with renal and adrenal, 6 (50%) with meningeal, and 3 (25%) with plurivisceral hemorrhage. From the 3 surfactant proteins analyzed, SPA is the only one that was proven to be found in extrapulmonary sites, although no protein expression was found in the corresponding tissues by previous immunohistochemistry studies.<sup>[41]</sup> An association between SPA deficit and renal and adrenal hemorrhage was found. New studies on mice have shown that SPA is also expressed in the renal tubular epithelial cells. SPA has a role in inflammation modulation and apoptosis in case of acute renal injury induced by sepsis.<sup>[42]</sup> Another surfactant protein, SPD, which was not analyzed in our study, was found to be produced in many extrapulmonary sites, such as the brain, salivary gland, lachrymal glands heart, prostate gland, kidney, all bladder and intrahepatic bile ducts, and pancreas.<sup>[43,44]</sup> This raises the question of whether SPD deficit may be associated with extrapulmonary lesions.

In summary, we found that premature twin newborns who died from RDS presented deficits of surfactant proteins SPA, SPB, and pro-SPC in fragments of organs with representative lesions taken from the autopsy. The pulmonary lesions identified at the autopsy were pulmonary hemorrhage, bronchopneumonia, and atelectasis. We also found numerous extrapulmonary lesions such as renal and adrenal hemorrhage, meningeal edema, and cerebral hemorrhage.

Although imaging and lung histopathology findings may strongly support a diagnosis of surfactant dysfunction, identifying additional genetic mechanisms is essential, as the inheritance patterns (and hence recurrence risk) and prognoses vary, depending upon the causative gene. Therefore, a multidisciplinary approach of clinical, genetic, epidemiologic, and histopathological considerations is necessary for an in-depth understanding of the pathophysiology of pulmonary diseases determined by protein surfactant deficiencies.

In this study, limitations to developing the utility of these observed surfactant proteins were a small number of cases from the studied group, because the newborns from twin pregnancies are not often met, marked heterogeneity in the clinical phenotype of cases, and no matching of cases for birth weight. There are more necessary cases to determine the association between surfactant deficits and pulmonary lesions, as well as determining the precise causes and pathogenesis of lung disease in preterm infants with RDS, to increase the survival rate.

## 5. Conclusions

Our analysis performed on deceased preterm twins suggests that surfactant protein deficiency is an important cause of mortality and morbidity. Low birth weight, fetal size at birth, GA, low 5-minute Apgar score, multiparity, and female gender of the fetuses were identified as risk factors for RDS caused by surfactant protein deficiency. We also identified numerous extrapulmonary lesions, preponderant hemorrhagic lesions with renal, adrenal, cerebral, and gastric localizations. Pulmonary hemorrhage was positively correlated with SPB expressions. Bronchopneumonia and 5-minute Apgar score were positively associated with the levels of SPA.

Future directions in this research area will be to study the genotype of surfactant proteins and the molecular functions of these genetic variants, which could contribute toward more effective, individualized prevention of respiratory failure and its serious consequences.

## Author contributions

S.-A.G, M.A., and G.C.C designed the research; M.E., A.-A.N., and G.-I.B. performed the experiments; N.D. and E.M. performed the statistical analysis and made the tables and figures;

N.D. is a certified specialist in biostatistics; E.M. is a certified specialist in biostatistics and computational uncertainty measurement and performance indicators in the laboratory; R.E.C., M.E., A.P.F., and G.C.C. wrote the manuscript.

## References

- [1] Santana DS, Silveira C, Costa ML, et al. Perinatal outcomes in twin pregnancies complicated by maternal morbidity: evidence from the WHO Multicountry Survey on Maternal and Newborn Health. *BMC Pregnancy Childbirth*. 2018;18:449.
- [2] Gao L, Lyu SP, Zhao XR, et al. Systematic management of twin pregnancies to reduce pregnancy complications. *Chin Med J (Engl)*. 2020;133:1355–7.
- [3] Ananth CV, Chauhan SP. Epidemiology of twinning in developed countries. *Semin Perinatol*. 2012;36:156–61.
- [4] Moss TJ. Respiratory consequences of preterm birth. *Clin Exp Pharmacol Physiol*. 2006;33:280–4.
- [5] Levit O, Jiang Y, Bizzarro MJ, et al. The genetic susceptibility to respiratory distress syndrome. *Pediatr Res*. 2009;66:693–7.
- [6] Somaschini M, Presi S, Ferrari M, et al. Surfactant proteins gene variants in premature newborn infants with severe respiratory distress syndrome. *J Perinatol*. 2018;38:337–44.
- [7] Howson CP, Kinney MV, Lawn J. March of dimes, PMNCH, save the children, WHO; born too soon: the global action report on preterm birth, 2012; 201204\_borntoosoon-report.pdf (who.int).
- [8] Cau F, Pisu E, Gerosa C, et al. Interindividual variability in the expression of surfactant protein A and B in the human lung during development. *Eur J Histochem*. 2016;60.
- [9] Bush A, Carlson KH, Zach M. Growing up with lung disease: the lung in transition to adult life. *European respiratory monograph*. 2002;7:1–24.
- [10] World Health Organization. ICD-10 International Statistical Classification of Diseases and Related Health Problems. Geneva: World Health Organization; 2004, ICD-10: international statistical classification of diseases and related health problems: tenth revision (who.int).
- [11] Kiserud T, Benachi A, Hecher K, et al. The World Health Organization fetal growth charts: concept, findings, interpretation, and application. *Am J Obstet Gynecol*. 2018;218:S619–29.
- [12] Opara EI, Zaidi J. The interpretation and clinical application of the word “parity”: a survey. *BJOG*. 2007;114:1295–7.
- [13] Abuelhamed WA, Zeidan N, Shahin WA, et al. Surfactant Proteins A2 (SP-A2) and B (SP-B) genes as determinants of respiratory distress syndrome. *Indian Pediatr*. 2015;52:391–4.
- [14] Mason RJ, Dobbs LG. Alveolar Epithelium and Pulmonary Surfactant. Murray and Nadel's Textbook of Respiratory Medicine (Sixth Edition), 2016; vol.1, p.134–49.
- [15] Ballard PL, Merrill JD, Godinez RI, et al. Surfactant protein profile of pulmonary surfactant in Premature Infants. *Am J Respir Crit Care Med*. 2003;168:1123–8.
- [16] Crouch E, Wright JF. Surfactant proteins A and D and pulmonary host defense. *Annu Rev Physiol*. 2001;63:521–54.
- [17] Nayak A, Dodagatta-Marri E, Tsolaki AG, et al. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. *Front Immunol*. 2012;3:131.
- [18] Smith LJ, McKay KO, van Aspen PP, et al. Normal development of the lung and premature birth. *Pediatr Respir Rev*. 2010;11:135–42.
- [19] Serrano AG, Cabre EJ, Perez-Gil J. Identification of a segment in the precursor of pulmonary surfactant protein SP-B, potentially involved in pH-dependent membrane assembly of the protein. *Biochim Biophys Acta*. 2007;1768:1059–69.
- [20] Parker TA, Kinsella JP. *Respiratory Disorders in the Term Infant, Very's Diseases of the Newborn (Tenth Edition)*, Ed. Elsevier, 2018; 668–77.
- [21] Glasser SW, Baatz JE, Korfhagen TR. Surfactant protein-C in the maintenance of lung integrity and function. *J Allerg Ther*. 2011;S7.
- [22] Bourbon JR, Chailley-Heu B. Surfactant proteins in the digestive tract, mesentery, and other organs: evolutionary significance. *Comp Biochem Physiol A Mol Integr Physiol*. 2001;129:151–61.
- [23] Verlato G, Cogo PE, Balzani M, et al. Surfactant status in preterm neonates recovering from respiratory distress syndrome. *Pediatrics*. 2008;122:102–8.
- [24] Pinheiro Ribeiro LP, de Albuquerque D. The importance of surfactant on the development of neonatal pulmonary diseases. *Clinics*. 2007;62:181–90.
- [25] American Academy of Pediatrics and American Heart Association. *Textbook of Neonatal Resuscitation*. 6th edition. Elk Grove Village, IL: American Academy of Pediatrics and American Heart Association; 2011; Neonatal resuscitation.pdf (moscmm.org).
- [26] Yadav S, Lee B, Kamity R. Neonatal Respiratory Distress Syndrome. In: *StatPearls Treasure Island (FL): StatPearls Publishing; 2021; Neonatal Respiratory Distress Syndrome - StatPearls - NCBI Bookshelf (nih.gov)*.
- [27] Donn SM, Sinha SK. Respiratory Distress Syndrome. *Manual of Neonatal Respiratory Care (Third Edition)*, 2017; p. 301–4.
- [28] Sun J, Qu S, Zhang C, et al. Neonatal mortality rate and risk factors in northeast China: analysis of 5277 neonates in 2005. *Clin Exp Obstet Gynecol*. 2014;41:512–6.
- [29] Sarinho SW, Moreira Filho DA, Silva GAP, et al. Fatores de risco para obitos neonatais no Recife: um estudo caso-controle. *J Pediatr*. 2001;77:294–8.
- [30] Vilanova CS, Hirakata VN, de Souza Buriol VC, et al. The relationship between the different low birth weight strata of new-borns with infant mortality and the influence of the main health determinants in the extreme south of Brazil. *Popul Health Metrics*. 2019;17:15.
- [31] Condo V, Cipriani S, Colnaghi M, et al. Neonatal respiratory distress syndrome: are risk factors the same in preterm and term infants? *J Matern Fetal Neonatal Med*. 2016;30:1267–72.
- [32] Liu J, Yang N, Liu Y. High-risk factors of respiratory distress syndrome in term neonates: a retrospective case-control study. *Balkan Med J*. 2014;31:64–8.
- [33] Chambliss Linda R, Bay Curtis R. The predictive value of a 5-minute appgar for developing respiratory distress syndrome. *Obstet Gynecol*. 2005;4:15.
- [34] Flenady V, Koopmans L, Middleton P, et al. Major risk factors for still-birth in the high-income countries: a systematic review and meta-analysis. *Lancet*. 2011;377:1331–40.
- [35] Wang S, Yang L, Shang L, et al. Changing trends of birth weight with maternal age: a cross-sectional study in Xi'an city of Northwestern China. *BMC Pregnancy Childbirth*. 2020;20:744.
- [36] Shiels MS, Kirk GD, Drummond MB, et al. HIV Infection and Circulating Levels Of Prosurfactant Protein B and surfactant Protein D. *J Infectious Diseases*. 2018;3:413–7.
- [37] Epaud R, Ikegami M, Whitsett JA, et al. Akinbi HT: surfactant protein B inhibits endotoxin-induced lung inflammation. *Am J Respir Cell Mol Biol*. 2003;28:373–8.
- [38] Nkadi PO, Merritt TA, Pillers DA. An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease. *Mol Genet Metab*. 2009;97:95–101.
- [39] Kishore U, Greenhough T, Waters P, et al. Surfactant proteins SP-A, and SP-D: structure, function and receptors. *Mol Immunol*. 2006;43:1293–315.
- [40] D'Aronco S, Simonato M, Vedovelli L, et al. Surfactant protein B and A concentrations are increased in neonatal pneumonia. *Pediatr Res*. 2015;78:401–6.
- [41] Kaditis AG, Motoyama EK, Zin W, et al. The effect of lung expansion and positive end-expiratory pressure on respiratory mechanics in anesthetized children. *Anesth Analg*. 2008;106:775–85, table of contents.
- [42] Madsen J, Tornoe I, Nielsen O, et al. Expression and localization of lung surfactant protein A in human tissues. *Am J Respir Cell Mol Biol*. 2003;29:591–7.
- [43] Liu J, Abdel-Razek O, Liu Z, et al. Role of surfactant proteins A and D in sepsis-induced acute kidney injury. *Shock*. 2015;43:31–8.
- [44] Madsen J, Kliem A, Tornoe I, et al. Localization of lung surfactant protein D on mucosal surfaces in human tissues. *J Immunol*. 2000;164:5866–70.